GPhC updates FtP hearings guidance with new discrimination directions

“Cultural differences” should now be considered in more detail by FtP committees after a GPhC vote on new guidance, the regulator has said.

Three-quarters of consultation respondents agreed with the proposed new discrimination guidance

The General Pharmaceutical Council (GPhC) has voted to accept changes to its fitness-to-practice (FtP) hearings and outcomes guidance at its council meeting last week (December 7), it has confirmed.

Free to registered users

Register to gain full access to C+D and C+D Community content

Sign in or register for free

James Stent

Read more by James Stent

James Stent joined C+D as a digital reporter in May 2023 from the South African human rights news agency GroundUp, where he was senior reporter and consultant editor.

Latest from News

BREAKING: Pharmacies to cut hours and services from April 1

 
• By 
 • comment0

The National Pharmacy Association (NPA) has announced that it is advising its 6,000 member pharmacies to limit services and reduce opening hours in protest against “unsustainable” funding.

Sebco coal tar scalp ointment appointed by DHSC to support current shortages

 • comment1

Due to shortages in coal tar scalp ointment, the DHSC has asked the manufacturer of an equivalent product - Sebco - to provide increased stock levels to support patients during this time.

Pharmacies to boost naloxone stock amid ‘sudden’ overdose spike

 
• By 
 • comment0

Pharmacies in Scotland have been asked to ensure they have the “appropriate stock” of naloxone – a medicine used to reverse the effects of an opiate overdose – following an “increase in sudden collapse” due to overdoses.

More from Business

breaking news

IN FULL: Boots’ parent company sold in $24bn private equity deal

 
• By 
 • comment8

Walgreens Boots Alliance (WBA) has “entered into a definitive agreement to be acquired” by private equity firm Sycamore Partners.

Jhoots accounts: Shareholder funds tumble while debts soar

 
• By 
 • comment2

Jhoots Chemist’s accounts for 2024 have revealed an almost £2 million year-on-year dip in shareholder funds – as debts to creditors increase more than £2m.